After Roche/Genentech: Pharma's Focus on Efficiencies, Not Innovation
Roche's rationale for buying Genentech must out-argue the one big reason not to do the deal: theirs has been the most successful relationship in pharmaceutical history. Instead, Roche is betting that this unique relationship has already borne its best fruit. In an emerging world of payor constraints, biological me-toos and growing oncology marketing expenses, the costs of keeping Genentech independent -- manufacturing transfer prices, up-front fees and royalties, and most importantly, no ability to leverage its investment in the US marketplace -- are simply too high. Moreover, Roche is clearly not convinced that Genentech's productivity would have continued at the rates it has in the last decade. Roche's vision of the pharma future looks a lot more like the cost-constrained world CEO Schwan knew at Roche Diagnostics - where innovation was rare and rarely paid for; where extraordinary business acumen counted for more than outsized research capabilities.
As IN VIVO was going to press, Roche announced it was offering $43.7 billion
for the 44% of Genentech Inc. it
didn’t already own. [See Deal]
The question is why? Certainly, Roche’s earnings are slowing and buying the remainder of Genentech will allow it to consolidate...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.
Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.
Advanced AI is revolutionizing sales enablement by addressing training gaps and performance challenges. Used correctly, it can help to bridge the sales-marketing divide, accelerate ramp-up times and provide managers with data-driven insights.
Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.
In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.
While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.